Valerie Israel
Overview
Explore the profile of Valerie Israel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hesketh P, Chansky K, Israel V, Grapski R, Mekhail T, Spiridonidis C, et al.
J Thorac Oncol
. 2007 May;
2(5):440-4.
PMID: 17473660
Background: This phase II study (S9718) evaluated the antineoplastic activity and tolerability of the combination of gemcitabine and cisplatin in previously untreated patients with extensive stage small cell lung cancer...
2.
Lara Jr P, Gumerlock P, Mack P, Lau D, Gandour-Edwards R, Edelman M, et al.
Clin Lung Cancer
. 2004 Oct;
6(2):102-7.
PMID: 15476595
A phase II trial was designed to evaluate the efficacy and toxicity of gemcitabine in patients with non-small-cell lung cancer (NSCLC) previously treated with platinum-containing regimens and prospectively categorized for...
3.
Israel V, Tagawa S, Snyder T, Jeffers S, Raghavan D
Invest New Drugs
. 2004 May;
22(3):291-7.
PMID: 15122076
Introduction: The poor prognosis of non small cell lung cancer (NSCLC), as well as the significant toxicity from many conventional cytotoxic regimens warrants the investigation of combinations of new active...
4.
Edelman M, Gandara D, Hausner P, Israel V, Thornton D, DeSanto J, et al.
Lung Cancer
. 2003 Feb;
39(2):197-9.
PMID: 12581573
Background: Cryptophycin 52 is a novel antitubulin drug with in vitro and in vivo activity in non-small cell lung cancer. Based upon promising Phase 1 data, a multicenter trial was...